CTOR (Citius Oncology) Total Operating Expense: $48.02 Mil (TTM As of Mar. 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.63
! 2 Warning Signs
View Full Analysis

What is Citius Oncology Total Operating Expense?

Citius Oncology CTOR -6.07% 10 Total Operating Expense is $48.02 Mil as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Citius Oncology's Total Operating Expense for the three months ended in Mar. 2026 was $29.95 Mil. Citius Oncology's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $48.02 Mil.

Citius Oncology Total Operating Expense Related Terms

Citius Oncology Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Citius Oncology's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology Total Operating Expense Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
Total Operating Expense
4.86 12.12 20.57 23.52

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.47 4.95 4.71 8.41 29.95
CTOR
10GF Score
Citius Oncology Inc CTOR
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $48.02 Mil mean?
Citius Oncology (CTOR) has a Total Operating Expense of $48.02 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Citius Oncology and its competitors.
Is Citius Oncology's Total Operating Expense too high?
Citius Oncology's current Total Operating Expense is $48.02 Mil. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Total Operating Expense compare to INCR and BGM?
Citius Oncology's Total Operating Expense of $48.02 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Citius Oncology and its competitors. Citius Oncology's current Total Operating Expense is $48.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Total Operating Expense of $48.02 Mil. The current Total Operating Expense is $48.02 Mil. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Total Operating Expense is $48.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.63
Price